drugset / Trial / NCT06092684

The Efficacy and Safety of Esketamine in Elective Laparoscopic Surgery

NCT06092684

Phase 3 Completed 358 enrolled Chengdu Brilliant Pharmaceutical Co., Ltd.
RandomizedParallel-groupQuadruple-blindTreatment

Summary

The objective is to evaluate the efficacy and safety of BT-KTM-I(Esketamine Hydrochloride Injection produced by Chengdu Brilliant Pharmaceutical Co., Ltd.) for general anesthesia, using the Originator drug Ketanest®S(Esketamine Hydrochloride Injection) as a positive control.

Timeline

Start
2023-09-20
Primary completion
2024-03-19
Completion
2024-03-19

Drugs

EvaluationDrugModalityDoseRoute
Subject Esketamine Other / unclassified 0.5 mg/kg

Indications

No indication recorded.